T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice
Priti Kumar,Hong Seok Ban,Sang-Soo Kim,Haoquan Wu,Todd Pearson,Dale L. Greiner,Amale Laouar,Jiahong Yao,Viraga Haridas,Katsuyoshi Habiro,Yong-Guang Yang,Ji Hoon Jeong,Kuen Yong Lee,Yong-Hee Kim,Sung Wan Kim,Matthias Peipp,Georg H. Fey,N. Manjunath,Leonard D. Shultz,Sang-Kyung Lee,Premlata Shankar +20 more
Reads0
Chats0
TLDR
SiRNA therapy for HIV infection appears to be feasible in a preclinical animal model and could deliver antiviral siRNAs to naive T cells in Hu-HSC mice and effectively suppress viremia in infected mice.About:
This article is published in Cell.The article was published on 2008-08-22 and is currently open access. It has received 555 citations till now. The article focuses on the topics: T cell & Small interfering RNA.read more
Citations
More filters
Journal ArticleDOI
Nonviral Vectors for Gene Delivery
TL;DR: Two nonviral gene delivery systems using either biodegradable poly(D,Llactide-co-glycolide) (PLG) nanoparticles or cell penetrating peptide (CPP) complexes have been designed and studied using A549 human lung epithelial cells.
Journal ArticleDOI
Therapeutic targeting of microRNAs: current status and future challenges
Zhonghan Li,Tariq M. Rana +1 more
TL;DR: Current knowledge of the design and performance of chemically modified miRNA-targeting antisense oligonucleotides is summarized, various in vivo delivery strategies are discussed and ongoing challenges to ensure the specificity and efficacy of therapeutic oligon nucleotides in vivo are analysed.
Journal ArticleDOI
Advances in oligonucleotide drug delivery
TL;DR: An overview of oligonucleotide-based drug platforms is provided, focusing on key approaches — including chemical modification, bioconjugation and the use of nanocarriers — which aim to address the delivery challenge.
Journal ArticleDOI
Humanized mice for immune system investigation: progress, promise and challenges.
TL;DR: This Review discusses recent advances in the development and utilization of humanized mice, the lessons learnt, the remaining challenges and the promise of using humanization mice for the in vivo study of human immunology.
Journal ArticleDOI
The current state and future directions of RNAi-based therapeutics.
TL;DR: This Review discusses key advances in the design and development of RNAi drugs leading up to this landmark achievement, the state of the current clinical pipeline and prospects for future advances, including novel RNAi pathway agents utilizing mechanisms beyond post-translational RNAi silencing.
References
More filters
Journal ArticleDOI
Latent infection of CD4 + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
Diana Finzi,Joel N. Blankson,Janet M. Siliciano,Joseph B. Margolick,Karen Chadwick,Theodore C. Pierson,Kendall A. Smith,Julianna Lisziewicz,Franco Lori,Charles Flexner,Thomas C. Quinn,Richard E. Chaisson,Eric S. Rosenberg,Bruce D. Walker,Stephen J. Gange,Joel E. Gallant,Robert F. Siliciano +16 more
TL;DR: The mean half-life of the latent reservoir was very long (43.9 months) and the decay rate of this latent reservoir in 34 treated adults whose plasma virus levels were undetectable as mentioned in this paper.
Journal ArticleDOI
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
Tae-Wook Chun,Lieven Stuyver,Stephanie B. Mizell,Linda A. Ehler,Jo Ann M. Mican,Michael Baseler,Alun L. Lloyd,Martin A. Nowak,Anthony S. Fauci +8 more
TL;DR: Highly purified CD4+ T cells from patients receiving HAART with an average treatment time of 10 months and with undetectable plasma viremia carried integrated proviral DNA and were capable of producing infectious virus upon cellular activation in vitro, suggesting persistent active virus replication in vivo.
Journal ArticleDOI
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways.
Dirk Grimm,Konrad L. Streetz,Konrad L. Streetz,Catherine L. Jopling,Theresa A. Storm,Kusum Pandey,Corrine R. Davis,Patricia L. Marion,Felix H. Salazar,Mark A. Kay +9 more
TL;DR: The risk of oversaturating endogenous small RNA pathways can be minimized by optimizing shRNA dose and sequence, as exemplified here by the report of persistent and therapeutic RNAi against human hepatitis B virus in vivo.
Journal ArticleDOI
RNA interference targeting Fas protects mice from fulminant hepatitis
Erwei Song,Sang-Kyung Lee,Jie Wang,Nedim Ince,Nengtai Ouyang,Jun Min,Jisheng Chen,Premlata Shankar,Judy Lieberman +8 more
TL;DR: In a more fulminant hepatitis induced by injecting agonistic Fas-specific antibody, 82% of mice treated with siRNA that effectively silenced Fas survived for 10 days of observation, whereas all control mice died within 3 days.
Journal ArticleDOI
Transvascular delivery of small interfering RNA to the central nervous system
Priti Kumar,Haoquan Wu,Jodi L. McBride,Kyeong Eun Jung,Moon Hee Kim,Beverly L. Davidson,Sang-Kyung Lee,Premlata Shankar,N. Manjunath +8 more
TL;DR: RVG-9R provides a safe and noninvasive approach for the delivery of siRNA and potentially other therapeutic molecules across the blood–brain barrier and afforded robust protection against fatal viral encephalitis in mice.
Related Papers (5)
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Jürgen Soutschek,Akin Akinc,Birgit Bramlage,Klaus Charisse,Rainer Constien,Mary Donoghue,Sayda Elbashir,Anke Geick,Philipp Hadwiger,Jens Harborth,Matthias John,Venkitasamy Kesavan,Gary Lavine,Rajendra K. Pandey,Timothy Racie,Kallanthottathil G. Rajeev,Ingo Röhl,Ivanka Toudjarska,Gang Wang,Silvio Wuschko,David Bumcrot,Victor Koteliansky,Stefan Limmer,Muthiah Manoharan,Hans-Peter Vornlocher +24 more